Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda raised a $311 million Series E at a $2 billion valuation to advance AI-discovered, nature-derived drugs into trials.
Enveda raised a $311 million Series E at a $2 billion valuation to advance nature-derived drugs discovered with AI. Catalio Capital Management led the round, with Iconiq and others participating, doubling the valuation Enveda reported 12 months earlier. Founded in 2019 by Viswa Colluru, an early Recursion Pharmaceuticals employee, the startup looks for medicines in plants and microbes rather than synthesizing them from scratch. It is already testing candidates in patients for severe skin conditions and for maintaining weight loss after GLP-1 treatment, though no AI-discovered drug has FDA approval yet.
- Series E of $311 million values Enveda at $2 billion.
- Catalio Capital Management led, with Iconiq participating.
- Valuation doubled compared with 12 months earlier.
- Trials cover severe skin disease and post-GLP-1 weight maintenance.
From the original article
1 min read at techcrunch.com
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
By Marina Temkin · techcrunch.com
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.